Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. Oct-Dec 2007;32(4):183-7.
doi: 10.1007/BF03191002.

Pharmacokinetics of Huperzine A Following Oral Administration to Human Volunteers

Clinical Trial

Pharmacokinetics of Huperzine A Following Oral Administration to Human Volunteers

Y X Li et al. Eur J Drug Metab Pharmacokinet. .


The objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20-25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5-10 min, and reached the peak concentrations with a Cmax of 2.59 +/- 0.37 ng/ml at 58.33 +/- 3.89 min (time to reach peak level, Tmax. The area under plasma vs time curve (AUC(0-t)) and the area under plasma from zero to infinity (AUC(0-infinity) for huperzine A were found to be 1986.96 +/- 164.57 microg/l.min and 2450.34 +/- 233.32 microg/l.min, respectively. The results of this study indicated that the pharmacokinetics of huperzine A conformed to a two-compartmental open model. The mean values of alpha and the beta half-life were 21.13 +/- 7.28 min and 716.25 +/- 130.18 min respectively, and showed a biphasic profile with rapid distribution followed by a slower elimination rate.

Similar articles

See all similar articles

Cited by 4 articles


    1. Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):396-8 - PubMed
    1. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):375-8 - PubMed
    1. Zhongguo Yao Li Xue Bao. 1996 Nov;17(6):481-4 - PubMed
    1. Rapid Commun Mass Spectrom. 2004;18(6):651-6 - PubMed
    1. Biomed Chromatogr. 2007 Jan;21(1):15-20 - PubMed

Publication types

LinkOut - more resources